ForumIAS LATEST
- 04 June | MGP Strategy Series | GS Paper 4 (Ethics) with AIR 7 A.R. Rajah Mohaideen Click Here to register for the session →
- 04 June | GS Advance Program begins from 4th June 2026 | First 2 classes open to all Click Here to register for the event →
- 05 June | MGP Strategy Series | GS Paper 3 Strategy Session with AIR 406 Mannat Luthra Click Here to register for the session
- 06 June | Open Orientation on Essay Guidance Program (EGP 2026) Click Here to register →
- 07 June | Open Orientation for Current Affairs for Mains 2026 Click Here to register →
- 07 June | Sociology Optional Strategy Session with AIR 10 Ujjwal Priyank Click Here to register →
News: The Endocrine Society has renamed Polycystic Ovary Syndrome (PCOS) as Polyendocrine Metabolic Ovarian Syndrome (PMOS) through a global medical consensus.
About Polyendocrine Metabolic Ovarian Syndrome (PMOS)
- PMOS is a hormonal and metabolic disorder that affects endocrine functions, metabolism, ovulation and overall women’s health.
- Key Aspects of PMOS:
- Hormonal and Metabolic Disorder: PMOS affects multiple hormone systems and is strongly linked with insulin resistance, obesity, diabetes risk and metabolic complications.
- Major Symptoms: Common symptoms include irregular or absent periods, excess androgen hormones, acne, facial hair growth, weight gain, difficulty losing weight and fertility challenges.
- Broader Health Impact: PMOS increases long-term risks of Type 2 diabetes, hypertension, heart disease, fatty liver disease, sleep disorders, depression and anxiety.
- Reproductive and Psychological Effects: The condition may lead to ovulatory dysfunction, infertility, pregnancy complications, anxiety, depression and poor quality of life.
- Diagnosis Challenges: Experts noted that PMOS is often underdiagnosed because symptoms vary widely and are frequently treated as cosmetic or lifestyle-related concerns.
- Indian Scenario: India is witnessing a rise in PMOS cases, especially among adolescents and young urban women, with studies showing prevalence ranging from 3.7% to over 22%.
- New Name Signifies:
- Earlier Name Was Misleading: The earlier term “Polycystic Ovary Syndrome” mainly focused on ovarian cysts, even though many women with the condition do not actually develop ovarian cysts.
- New Name Reflect: The new term “Polyendocrine Metabolic Ovarian Syndrome” was introduced to reflect the multisystem nature of the disorder, which affects hormone systems, metabolism, ovulation, reproductive health and long-term overall health.
